Alexandria Pharmaceuticals results, Q1 2022
Net profit, assets, equity and cash flow for Q1 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit33.23 millionEGP
Total assets885 millionEGP
Shareholders' equity553 millionEGP
Operating cash flow37.25 millionEGP
In short
- Alexandria Pharmaceuticals's net profit for Q1 2022 was about 33.23 million EGP.
- Total assets at the end of Q1 2022 were about 885 million EGP, and shareholders' equity about 553 million EGP.
- Operating cash flow for Q1 2022 was positive at 37.25 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit33.23 million——
Gross profit74.17 million——
Total assets885 million——
Total liabilities332 million——
Shareholders' equity553 million——
Total liabilities and equity885 million——
Operating cash flow37.25 million——
Investing cash flow-14.38 million——
Financing cash flow-289 thousand——
Net change in cash22.57 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy